Page 150 - Read Online
P. 150

Balasubramaniam et al. J Transl Genet Genom 2020;4:285-306  I  http://dx.doi.org/10.20517/jtgg.2020.34                   Page 301

               Conflicts of interest
               Both authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.

               REFERENCES
               1.   Lienhart WD, Gudipati V, Macheroux P. The human flavoproteome. Arch Biochem Biophys 2013;535:150-62.
               2.   Joosten V, van Berkel WJ. Flavoenzymes. Curr Opin Chem Biol 2007;11:195-202.
               3.   Balasubramaniam S, Christodoulou J, Rahman S. Disorders of riboflavin metabolism. J Inherit Metab Dis 2019;42:608-19.
               4.   Kennedy DO. B Vitamins and the brain: mechanisms, dose and efficacy-a review. Nutrients 2016;8:68.
               5.   Barile M, Giancaspero TA, Leone P, Galluccio M, Indiveri C. Riboflavin transport and metabolism in humans. J Inherit Metab Dis
                   2016;39:545-57.
               6.   Henriques BJ, Rodrigues JV, Gomes CM. Riboflavin and b-oxidation flavoenzymes. In: Preedy VR, editor. B vitamins and folate:
                   chemistry, analysis, function and effects (Food and nutritional components in focus series No. 4). Cambridge: The Royal Society of
                   Chemistry Publishing; 2013. pp. 611-30.
               7.   Mosegaard S, Dipace G, Bross P, Carlsen J, Gregersen N, et al. Riboflavin Deficiency-Implications for general human health and inborn
                   errors of metabolism. Int J Mol Sci 2020;21:E3847.
               8.   McCormick DB. Two interconnected B vitamins: riboflavin and pyridoxine. Physiol Rev 1989;69:1170-98.
               9.   Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am
                   J Clin Nutr 1996;63:54-66.
               10.  Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr 2003;77:1352-6130.
               11.  Chastain JL, McCormick DB. Flavin catabolites: identification and quantitation in human urine. Am J Clin Nutr 1987;46:830-4.
               12.  Suomalainen A, Battersby BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol
                   2017;19:77-92.
               13.  Gorman GS, Chinnery PF, DiMauro S, Hirano M, Kogaet Y, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080.
               14.  Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 1985;54:1015-69.
               15.  Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst)
                   2006;5:145-52.
               16.  Ross WN. Understanding calcium waves and sparks in central neurons. Nat Rev Neurosci 2012;13:157-68.
               17.  Niyazov DM, Kahler SG, Frye R. Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for
                   diagnosis and treatment. Mol Syndromol 2016;7:122-37.
               18.  Yonezawa A, Masura S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter,
                   RFT1. Am J Physiol Cell Physiol 2008;295:C632-41.
               19.  Yonezawa A, Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and
                   genetic diseases of RFVT/SLC52. Mol Aspects Med 2013;34,693-701.
               20.  Yamamoto S, Inque K, Ohta KY, Fukatsu R, Maeda J, et al. Identification and functional characterization of rat riboflavin transporter 2. J
                   Biochem 2009;145:437-43.
               21.  Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, et al. Identification and comparative functional characterization of a new human
                   riboflavin transporter hRFT3 expressed in the brain. J Nutr 2010;140:1220-6.
               22.  Bosch AM, Abeling NG, Ijlst L, Knoester H, van der Pol WL, et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated
                   with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab
                   Dis 2011;34:159-64.
               23.  Green P, Wiseman M, Crow YJ, Houlden H, Riphagenet S, et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with
                   deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010;86:485-9.
               24.  Dipti S, Childs AM, Livingston JH, Aggarwal AK, Miller M, et al. Brown-Vialetto-Van Laere syndrome; variability in age at onset and
                   disease progression highlighting the phenotypic overlap with Fazio-Londe disease. Brain Dev 2005;27:443-6.
               25.  Manole A, Houlden H. Riboflavin transporter deficiency neuronopathy. In: GeneReviews  [Internet]. Seattle (WA): University of
                                                                               ®
                   Washington; 1993-2020.
               26.  O’Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin
                   transporter deficiency. J Inherit Metab Dis 2019;42:598-607.
   145   146   147   148   149   150   151   152   153   154   155